Abstract
The persistence of resistance, recurrence, and limited selectivity in cancer therapy necessitates the development of structurally advanced antitumor agents capable of modulating multiple intracellular pathways. This review provides a systematic analysis of nitrogen- and oxygen-containing heterocycles as key platforms in anticancer drug design, with an emphasis on integrated molecular architectures combining multiple pharmacophoric fragments. A central and unifying principle emerging from the analyzed studies is the decisive role of hydrazide–hydrazone functionalization as a pharmacophoric enhancer, which should be considered not merely as a substituent but as a core structural element governing conformational flexibility, electronic distribution, and target-binding efficiency. Its incorporation consistently correlates with enhanced antiproliferative activity, apoptosis induction, and improved selectivity across diverse tumor models. Within this framework, the most efficient representatives highlight the practical significance of this design strategy: compound 17 demonstrates exceptional activity with GI 50 values of 0.01–0.1 μM among N-heterocyclic systems, while compound 40 emerges as a leading O-heterocyclic analogue, exhibiting IC 50 values of 0.45 μg/mL against MCF-7 cells. Collectively, these findings support the strategic prioritization of hydrazide-centered heterocyclic scaffolds as a foundation for the rational development of next-generation anticancer therapeutics.